NCT03969888

A Phase 2 Study of an Active Drug Alone and in Combination With an Active Drug

Brief summary

This study will evaluate the safety, tolerability, and efficacy of an active drug given alone and in combination with various doses of an active drug in adults with Cystic Fibrosis who are homozygous for the F508del mutation.

Interventional

Interventional study

Status:
Completed
Conditions:
Cystic Fibrosis
Enrollment:
78 patients
Phase:
  • 1
  • 2
  • 3
  • 4
Protocol ID:
M19-530
Allocation:
Randomized
Intervention model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Purpose:
Treatment

 

Eligibility criteria

Participant attributes:
Male and Female

Age:

18 Years and older.

Inclusion Criteria:

- Confirmed clinical diagnosis of Cystic Fibrosis (CF) who are homozygous for the
F508del CF transmembrane conductance regulator (CFTR) mutation

- Stable pulmonary status

- Lung function >= 40 and <= 90% of predicted normal for age, gender and height at
Screening

Exclusion Criteria:

- History of solid organ or hematopoietic transplant

- Cirrhosis with portal hypertension

- Use of CFTR modulator therapy within 60 days prior to Screening

All the cities where the clinical studies are located

Toronto - M5B 1W8

Alberta

Calgary

British Columbia

Vancouver

Nova Scotia

Halifax

Ontario

Toronto

Quebec

Montreal
Québec

More information about this study

clinicaltrials.gov